• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

CMP Pharma Releases Liqrev, First FDA-Approved Liquid Suspension of Sildenafil

Article

Medicine created for patients with difficulty swallowing tablets.

Close up of pipette with pouring liquid essential oil on green nature background. Dropper with a falling drop of aromatherapy oil close-up. Beauty, wellness and body care. Image Credit: Adobe Stock Images/dmytro_khlystun

Image Credit: Adobe Stock Images/dmytro_khlystun

CMP Pharma, a pharmaceutical manufacturer, announced that Liqrev, the first FDA-approved ready-made oral liquid of sildenafil, is now available. Created for patients with the inability to swallow tablets, the medication is designated for the treatment of pulmonary arterial hypertension.

"Liqrev is for patients who need a liquid formulation because they have difficulty swallowing tablets. This product is a nice addition to our portfolio of liquids for patients with pulmonary arterial hypertension (PAH)," said Gerald Sakowski, CEO, CMP Pharma, Inc.

Reference: CMP Pharma, Inc Announces that Liqrev®, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available. PR Newswire. June 21, 2023. Accessed June 22, 2023. https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-liqrev-the-first-and-only-ready-made-fda-approved-liquid-suspension-of-sildenafil-is-now-available-301856229.html

Recent Videos
Related Content